Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid epidemic

U.S. to Promote Use of Opioid Alternatives to Treat Addiction

Toni Clarke  |  October 26, 2017

(Reuters)—The U.S. Food and Drug Administration plans to encourage opioid addicts to use less harmful opioid drugs such as methadone and buprenorphine, a radical shift in policy that could agitate those in the addiction field who believe abstinence is the only effective treatment. Speaking before the House Committee on Energy and Commerce on Wednesday, FDA…

Filed under:Drug Updates Tagged with:addiction treatmentbuprenorphineFDA Commissioner Scott Gottliebmethadonenational opioid addiction epidemicopioid alternativesopioid crisisopioid substituteU.S. Food and Drug Administration (FDA)

Rhode Island Doctor Pleads Guilty to Opioid Kickback Scheme

Nate Raymond  |  October 26, 2017

BOSTON (Reuters)—A Rhode Island doctor pleaded guilty on Wednesday to charges he participated in a scheme to obtain kickbacks in exchange for writing prescriptions for an addictive fentanyl-based cancer pain drug produced by Insys Therapeutics Inc. The plea by Jerrold Rosenberg came amid ongoing investigations of Insys related to Subsys, an under-the-tongue spray that contains…

Filed under:EthicsLegal Updates Tagged with:Cancerfentanyl-based cancer pain drugguilty pleahealthcare fraudInsys Therapeutics IncJerrold Rosenbergnational opioid addiction epidemicopioid crisisopioid kickback schemeRhode Island doctor

New Jersey Sues Insys as Opioid Maker Settles with Massachusetts

Nate Raymond  |  October 5, 2017

BOSTON (Reuters)—New Jersey on Thursday accused Insys Therapeutics Inc of engaging in a fraudulent scheme to boost sales of a fentanyl-based cancer pain drug, as Massachusetts announced a $500,000 settlement with the drugmaker to resolve similar allegations. The lawsuit by New Jersey Attorney General Christopher Porrino accused Insys of illegally directing its sales force to…

Filed under:Drug UpdatesLegal Updates Tagged with:Cancerfentanyl-based cancer pain drugInsys Therapeutics IncNew Jersey Attorney General Christopher PorrinoNew Jersey lawsuitopioid crisis

Unbudgeted: How the Opioid Crisis Is Blowing a Hole in Small-Town America’s Finances

Paula Seligson & Tim Reid  |  September 20, 2017

INDIANA, Pa./CHILLICOTHE, Ohio (Reuters)—As deaths mount in America’s opioid crisis, communities on the front lines face a hidden toll: the financial cost. Ross County, a largely rural region of 77,000 people an hour south of Columbus, Ohio, is wrestling with an explosion in opioid-related deaths—44 last year compared with 19 in 2009. The drug addiction…

Filed under:AnalgesicsDrug Updates

Prosecutors Identify Insys Founder as Unindicted Co-conspirator in Opioid Case

Nate Raymond  |  September 14, 2017

BOSTON (Reuters)—U.S. prosecutors have identified Insys Therapeutics Inc’s billionaire founder as an unindicted co-conspirator in a case accusing six former executives and managers of participating in a scheme that involved bribing doctors to prescribe a fentanyl-based drug, according to a court document. John Kapoor, who stepped down as chief executive of Insys in January, was…

Filed under:Legal Updates Tagged with:Insys Therapeutics IncJohn Kapooropioid crisisopioid drug companiesOpioid drugmaker probe

U.S. Senator Reveals Results of Opioid Inquiry into Insys

Nate Raymond  |  September 7, 2017

BOSTON (Reuters)—Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday. The report, released by Democratic Senator Claire McCaskill, said those efforts led to an Insys employee making misleading statements…

Filed under:Drug UpdatesLegal Updates Tagged with:Insys Therapeutics Incopioid crisisSubsys opioid drugU.S. Democratic Senator Claire McCaskillU.S. Senate report

Trump Declares National Emergency on Opioid Abuse

James Oliphant  |  August 10, 2017

BEDMINSTER, N.J. (Reuters)—U.S. President Donald Trump on Thursday declared the opioid epidemic a national emergency and said his administration was drafting papers to make it official. “The opioid crisis is an emergency and I’m saying officially right now it is an emergency,” Trump told reporters in New Jersey. “We’re going to draw it up and…

Filed under:Drug Updates Tagged with:national emergencyopioid crisisopioid epidemic

New Hampshire Sues Purdue Pharma over Opioid Marketing

Nate Raymond  |  August 8, 2017

(Reuters)—New Hampshire sued OxyContin maker Purdue Pharma LP on Tuesday, joining several state and local governments in accusing the drugmaker of engaging in deceptive marketing practices that have helped fuel a national opioid addiction epidemic. The lawsuit filed in Merrimack County Superior Court claimed that Purdue Pharma significantly downplayed the risk of addiction posed by…

Filed under:AnalgesicsDrug UpdatesLegal Updates Tagged with:lawsuitLegalOpioid abuseopioid crisisOpioidsOxyContinpharmaceutical companyPurdue Pharma LP

DEA Proposes Cutting Production of Come Opioids

Reuters Staff  |  August 7, 2017

(Reuters)—The U.S. Drug Enforcement Administration (DEA) on Friday proposed a 20% reduction in the manufacture of certain commonly prescribed opioid painkillers, as well as other controlled substances for next year. The proposal comes as U.S. regulators and lawmakers take steps to limit the supply of opioids—a class of drugs that include prescription painkillers and heroin—to…

Filed under:AnalgesicsDrug Updates Tagged with:Opioid abuseopioid crisisOpioids

U.S. Senator Expands Opioid Probe to Distributors, Drugmakers

Reuters Staff  |  July 27, 2017

(Reuters)—U.S. Democratic Senator Claire McCaskill on Thursday expanded an investigation into the causes of the opioid crisis plaguing the country, seeking information from four more drugmakers and three drug distributors. The top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee is focusing on the distribution of opioids and the efforts companies made to…

Filed under:Drug UpdatesLegal Updates Tagged with:Allergan Plc.Endo International PlcMallinckrodt Plcopioid crisisOpioid probeTeva PharmaceuticalsU.S. Democratic Senator Claire McCaskill

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences